Bausch + Lomb Corp's stock surged by 3.22% in the last trading session, driven by positive financial results and an optimistic outlook.
In a notable move on the TSX, Bausch + Lomb Corp (BLCO.TO) experienced a 3.22% increase, closing at CA$21.78. This uptick follows the companyโs announcement of strong financial results and an upward revision of its full-year guidance, boosting investor sentiment.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.16B
52W high
$25.70
52W low
$18.24
1W change
-5.71%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to fall 17.6% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.92
-17.6% Upside
Current Price
C$22.96
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
32.9%
Annualized
90-Day Vol
31.1%
Annualized
Trend (90d)
+2.8%
Annualized drift
90d Mean
C$23.19
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$23.04 | C$20.56 โ C$25.81 |
| 60 trading days | C$23.11 | C$19.68 โ C$27.14 |
| 90 trading days | C$23.19 | C$19.05 โ C$28.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should pay attention to Bausch + Lomb's recent performance and the implications of its raised guidance, as it may signal a positive trajectory for the company in the near future.
Bausch + Lomb's stock rises 3.22% in one day
With a market cap of CA$7.61 billion, Bausch + Lomb is positioning itself for growth amidst a competitive landscape.
Bull case
Bausch + Lomb's recent financial results show that the company is effectively navigating market challenges. The raised guidance reflects confidence in sustained growth. The launch of new products like Soothe Antibiotic Drops could further boost revenue.
Bear case
Despite the positive movement, the company's negative profit margin and lack of a dividend yield might concern more conservative investors. Additionally, market volatility could affect future performance.
Strong Financial Performance
Bausch + Lomb recently announced its first-quarter 2026 financial results, showcasing a robust performance that exceeded market expectations. This has led to a raised full-year guidance, reflecting the company's confidence in its operational strategy and market conditions.
Product Innovations Driving Growth
The launch of Soothe Antibiotic Drops in Canada marks a significant step for Bausch + Lomb in expanding its product offerings. This over-the-counter treatment addresses external bacterial infections, potentially increasing the company's market share in the eye care segment.
Market Reaction and Future Outlook
The positive market reaction to Bausch + Lomb's recent announcements indicates investor optimism. However, potential investors should remain cautious about the company's profit margins and overall market volatility as they assess future investment opportunities.
Advertisement
